BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

518 related articles for article (PubMed ID: 28513830)

  • 1. Association between mutations of critical pathway genes and survival outcomes according to the tumor location in colorectal cancer.
    Lee DW; Han SW; Cha Y; Bae JM; Kim HP; Lyu J; Han H; Kim H; Jang H; Bang D; Huh I; Park T; Won JK; Jeong SY; Park KJ; Kang GH; Kim TY
    Cancer; 2017 Sep; 123(18):3513-3523. PubMed ID: 28513830
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of pathway mutation with survival after recurrence in colorectal cancer patients treated with adjuvant fluoropyrimidine and oxaliplatin chemotherapy.
    Lee DW; Han SW; Cha Y; Bae JM; Kim HP; Lyu J; Han H; Kim H; Jang H; Bang D; Won JK; Jeong SY; Park KJ; Kang GH; Kim TY
    BMC Cancer; 2019 May; 19(1):421. PubMed ID: 31060539
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Li AJ; Li HG; Tang EJ; Wu W; Chen Y; Jiang HH; Lin MB; Yin L
    World J Gastroenterol; 2018 Feb; 24(5):631-640. PubMed ID: 29434452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Associations between primary tumor RAS, BRAF and PIK3CA mutation status and metastatic site in patients with chemo-resistant metastatic colorectal cancer.
    Christensen TD; Palshof JA; Larsen FO; Poulsen TS; Høgdall E; Pfeiffer P; Jensen BV; Yilmaz MK; Nielsen D
    Acta Oncol; 2018 Aug; 57(8):1057-1062. PubMed ID: 29380640
    [TBL] [Abstract][Full Text] [Related]  

  • 5. KRAS and PIK3CA mutations in colorectal adenocarcinomas correlate with aggressive histological features and behavior.
    Jang S; Hong M; Shin MK; Kim BC; Shin HS; Yu E; Hong SM; Kim J; Chun SM; Kim TI; Choi KC; Ko YW; Kim JW
    Hum Pathol; 2017 Jul; 65():21-30. PubMed ID: 28188750
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence and coexistence of KRAS, BRAF, PIK3CA, NRAS, TP53, and APC mutations in Indian colorectal cancer patients: Next-generation sequencing-based cohort study.
    Jauhri M; Bhatnagar A; Gupta S; Bp M; Minhas S; Shokeen Y; Aggarwal S
    Tumour Biol; 2017 Feb; 39(2):1010428317692265. PubMed ID: 28222664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The potential of PIK3CA, KRAS, BRAF, and APC hotspot mutations as a non-invasive detection method for colorectal cancer.
    Alizadeh-Sedigh M; Mahmoodzadeh H; Fazeli MS; Haddadi-Aghdam M; Teimoori-Toolabi L
    Mol Cell Probes; 2022 Jun; 63():101807. PubMed ID: 35296442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutation location on the RAS oncogene affects pathologic features and survival after resection of colorectal liver metastases.
    Frankel TL; Vakiani E; Nathan H; DeMatteo RP; Kingham TP; Allen PJ; Jarnagin WR; Kemeny NE; Solit DB; D'Angelica MI
    Cancer; 2017 Feb; 123(4):568-575. PubMed ID: 27737491
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phosphorylation of p70 Ribosomal Protein S6 Kinase β-1 is an Independent Prognostic Parameter in Metastatic Colorectal Cancer.
    Wiesweg M; Reis H; Köster T; Goetz M; Worm K; Herold T; Paul A; Dechêne A; Schumacher B; Markus P; Virchow I; Kostbade K; Wolf N; Zaun G; Metzenmacher M; Schmid KW; Schuler M; Kasper S
    Clin Colorectal Cancer; 2018 Jun; 17(2):e331-e352. PubMed ID: 29526493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FOLFOX4 Plus Cetuximab for Patients With Previously Untreated Metastatic Colorectal Cancer According to Tumor RAS and BRAF Mutation Status: Updated Analysis of the CECOG/CORE 1.2.002 Study.
    Kaczirek K; Ciuleanu TE; Vrbanec D; Marton E; Messinger D; Liegl-Atzwanger B; Wrba F; Knittelfelder R; Lindner E; Zielinski CC; Streubel B; Brodowicz T
    Clin Colorectal Cancer; 2015 Jun; 14(2):91-8. PubMed ID: 25666295
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PIK3CA mutation is predictive of poor survival in patients with colorectal cancer.
    Kato S; Iida S; Higuchi T; Ishikawa T; Takagi Y; Yasuno M; Enomoto M; Uetake H; Sugihara K
    Int J Cancer; 2007 Oct; 121(8):1771-8. PubMed ID: 17590872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of neuroendocrine differentiation and KRAS/NRAS/BRAF/PIK3CA/TP53 mutation status in primary and metastatic colorectal cancer.
    Kleist B; Kempa M; Novy M; Oberkanins C; Xu L; Li G; Loland C; Poetsch M
    Int J Clin Exp Pathol; 2014; 7(9):5927-39. PubMed ID: 25337237
    [TBL] [Abstract][Full Text] [Related]  

  • 13. APC and PIK3CA Mutational Cooperativity Predicts Pathologic Response and Survival in Patients Undergoing Resection for Colorectal Liver Metastases.
    Yamashita S; Chun YS; Kopetz SE; Maru D; Conrad C; Aloia TA; Vauthey JN
    Ann Surg; 2020 Dec; 272(6):1080-1085. PubMed ID: 28379870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genomic Sequencing and Insight into Clinical Heterogeneity and Prognostic Pathway Genes in Patients with Metastatic Colorectal Cancer.
    Kawaguchi Y; Kopetz S; Kwong L; Xiao L; Morris JS; Tran Cao HS; Tzeng CD; Chun YS; Lee JE; Vauthey JN
    J Am Coll Surg; 2021 Aug; 233(2):272-284.e13. PubMed ID: 34111531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutation Status of
    Kawaguchi Y; Kopetz S; Newhook TE; De Bellis M; Chun YS; Tzeng CD; Aloia TA; Vauthey JN
    Clin Cancer Res; 2019 Oct; 25(19):5843-5851. PubMed ID: 31221662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer.
    Juanpere N; Agell L; Lorenzo M; de Muga S; López-Vilaró L; Murillo R; Mojal S; Serrano S; Lorente JA; Lloreta J; Hernández S
    Hum Pathol; 2012 Oct; 43(10):1573-82. PubMed ID: 22417847
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical impact of K-ras mutation in colorectal cancer patients treated with adjuvant FOLFOX.
    Chang MH; Lee IK; Si Y; Lee KS; Woo IS; Byun JH
    Cancer Chemother Pharmacol; 2011 Aug; 68(2):317-23. PubMed ID: 20972872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Major challenges related to tumor biological characteristics in accurate mutation detection of colorectal cancer by next-generation sequencing.
    Li W; Qiu T; Guo L; Ying J
    Cancer Lett; 2017 Dec; 410():92-99. PubMed ID: 28942013
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PI3K Pathway Alterations in Peritoneal Metastases are Associated with Earlier Recurrence in Patients with Colorectal Cancer Undergoing Optimal Cytoreductive Surgery.
    Peerenboom R; Dhiman A; Witmer HDD; Spurr LF; Polite B; Eng OS; Shergill A; Turaga KK
    Ann Surg Oncol; 2023 May; 30(5):3114-3122. PubMed ID: 36637640
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor Mutation Burden and Prognosis in Patients with Colorectal Cancer Treated with Adjuvant Fluoropyrimidine and Oxaliplatin.
    Lee DW; Han SW; Bae JM; Jang H; Han H; Kim H; Bang D; Jeong SY; Park KJ; Kang GH; Kim TY
    Clin Cancer Res; 2019 Oct; 25(20):6141-6147. PubMed ID: 31285374
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.